Header
For Healthcare Professionals

India: 3 WAYS TO POWERFUL EFFICACY

Efficacy banner(why glyxambi)
Addresses multiple defects
Addresses multiple defects of 8/8 Ominous octet pathway7, 9
Reduction in body weight
Body weight (-3kg↓)6 & Insulin Resistance (46%↓)7
Improves ß-cell functioning
Improves ß-cell functioning by 
35%↑8
HbA1c banner image

1.8% HbA1c reduction6

mean baseline 9.06%

Glyxambi works in 3 pathways for powerful efficacy6,7,8

 
Glyxambi works in 3 pathways banner

RETHINK THE MATH to manage T2DM

References

  1. GLYXAMBI® India pack insert version. 15 May 2024.

  2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

  3. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.

  4. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166.

  5. Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(18):1801-1802.

  6. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-393. 

  7. Hattori S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr. 2018;10:93. 

  8. Del Prato, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258-267 

  9. Thrasher J. Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004. PMID: 28526182.